Apply to trial NCT04270591

A few quick questions so the study team can decide if you might be a fit.

RecruitingDrug trial

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Indication:Patients with Advanced c-MET-positive Non-Small Cell Lung Cancer Phase Ib (China only): Approximately 90 patients Phase Ⅱ (globally): Approximately 78 evaluable patients; addition of at least 6 patients in Safety Run-in (US only)

How this works

  1. Answer a few questions

    About 5 to 10 minutes. Skip-friendly where possible.

  2. We forward your profile to the study team

    We send your contact details and a short fit summary to the official trial contacts, with you copied.

  3. The team reaches out to schedule screening

    Usually within a few business days, via the contact you give.

We save your progress under this email and copy you when we send your application to the study team.

By clicking Start, you agree to our terms of service, including sharing your contact details and fit summary with official trial contacts if you submit.